|
PJA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.89860000130582E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.54089999995877E-06 |
| Normal-vs-Stage2 |
1.238110E-03 |
| Normal-vs-Stage3 |
6.46350000188534E-08 |
| Normal-vs-Stage4 |
2.70550000180947E-08 |
| Stage1-vs-Stage2 |
7.805000E-01 |
| Stage1-vs-Stage3 |
1.942810E-01 |
| Stage1-vs-Stage4 |
2.381600E-02 |
| Stage2-vs-Stage3 |
2.421400E-01 |
| Stage2-vs-Stage4 |
7.808000E-02 |
| Stage3-vs-Stage4 |
3.599800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.89390000349121E-08 |
| Normal-vs-AfricanAmerican |
7.050500E-02 |
| Normal-vs-Asian |
1.79216999999232E-05 |
| Caucasian-vs-AfricanAmerican |
8.168100E-02 |
| Caucasian-vs-Asian |
8.814000E-01 |
| AfricanAmerican-vs-Asian |
1.113220E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.41239999695841E-08 |
| Normal-vs-Female |
1.19200000003872E-06 |
| Male-vs-Female |
1.436550E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.46809999999909E-05 |
| Normal-vs-Age(41-60Yrs) |
1.98409999985216E-07 |
| Normal-vs-Age(61-80Yrs) |
1.43960000031917E-07 |
| Normal-vs-Age(81-100Yrs) |
3.564100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.061800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.925600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.490400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.350400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.946800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.494800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.055500E-02 |
| Classical-VS-Follicular |
6.218200E-01 |
| Classical-VS-Other |
1.069590E-01 |
| Classical-VS-Normal |
2.25030000000626E-06 |
| Tall-VS-Follicular |
1.467200E-01 |
| Tall-VS-Other |
4.155800E-01 |
| Tall-VS-Normal |
2.31179999998776E-06 |
| Follicular-VS-Other |
2.136600E-01 |
| Follicular-VS-Normal |
1.035250E-04 |
| Other-VS-Normal |
1.480980E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.49020000023748E-07 |
| Normal-vs-N1 |
7.36220000518983E-08 |
| N0-vs-N1 |
1.400420E-01 |
|
|
